Hims & Hers Stock Jumps 85.1% in 3 Months: Is It a Buy Now?

Hims & Hers (HIMS) stock has surged 85.1% in the last three months, driven by strategic initiatives including the acquisition of ZAVA, a partnership with Novo Nordisk to offer Wegovy at $549 per month, and an $870 million convertible notes offering to fund global expansion and AI investments. The company projects Q2 2025 revenue growth of 68-74% year-over-year, reaching $530-$550 million, and anticipates full-year revenue between $2.3-$2.4 billion, despite a gross margin contraction in Q1 2025 due to rising product costs.

Analysis

Hims & Hers Health, Inc. (HIMS) has demonstrated remarkable stock performance, surging 85.1% over the past three months, significantly outperforming its industry's 16.8% gain, the S&P 500's 5.6% rise, and the notable share price declines of competitors Teladoc Health (-13.7%) and American Well Corporation (-13.3%). This momentum is underpinned by key strategic initiatives, including an agreement to acquire European digital health platform ZAVA, a partnership with Novo Nordisk to offer prescription Wegovy at an accessible $549 per month, and an $870 million convertible notes offering aimed at financing global expansion, AI development, and personalized treatments. Reflecting these growth drivers, HIMS projects robust Q2 2025 revenue between $530-$550 million, a 68-74% year-over-year increase, and full-year 2025 revenue of $2.3-$2.4 billion, representing a 56-63% increase from 2024 levels. Analyst sentiment corroborates this positive outlook, with Zacks Consensus Estimates for 2025 earnings per share rising 17.7% to 73 cents in the past 60 days. However, the company reported lower wholesale revenues and a significant 886 basis point contraction in gross margin in Q1 2025 due to higher product costs, a factor requiring careful management. HIMS' forward 12-month price-to-sales ratio stands at 5.3x, below the industry average of 6x but above its five-year median of 2.6x, suggesting a valuation that reflects strong growth expectations yet may still offer upside relative to the industry if execution remains strong.

Key Decisions for Investors

• Investors should acknowledge Hims & Hers' substantial growth potential fueled by international expansion, particularly the ZAVA acquisition, new high-demand product offerings like Wegovy through the Novo Nordisk partnership, and AI-driven personalization initiatives.
• Vigilantly monitor the company's ability to manage rising product costs and address the gross margin pressure observed in Q1 2025, where margins contracted by 886 basis points, as this is crucial for sustained profitability.
• Evaluate the stock's valuation; while the forward P/S ratio of 5.3x is below the industry average, it is considerably above its historical median and those of peers like Teladoc Health and Amwell, indicating that continued strong execution on revenue growth and strategic initiatives is critical to justify its current market valuation and support further appreciation.